Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up    |  Already a member? Sign In
Pharma IQ

Developing a Single Product for Multiple Markets


This FREE webinar was recorded on:
Tuesday, October 25, 2011, 12:00 PM - 1:00 PM ET
Panelist: Dominic Wall

Rate this Webinar: (4.8 Stars | 40 Votes)

Tags: cell therapies




Sponsor

Register

Meeting the manufacturing requirements of FDA, EMEA and TGA is a common challenge for those undertaking product development in the context of multicentre studies.

When optimising a product to ensure its commercial viability what can be done to pre-empt likely concerns of multiple regulators?

This webinar will take you through the common issues and points of difference between each regulator. As well as addressing the challenges and opportunities when using manufacturing sites on three continents.

At which point should automation and introduction of closed systems be optimally considered?

Dominic will also explore product development, biomaterials, comparability, stability and in process and release testing as well as  product characterisation.
 


Panelist:

Dominic Wall
Dominic Wall
PhD FFSc (RCPA)
Cell Therapies

Dominic Wall has been directly involved in cell therapy manufacturing since the 1990’s and is currently the Chief Scientific Officer of Cell Therapies Pty Ltd  as well as being the the operations director of the cell therapy services (and pathology services) at a comprehensive cancer centre (Peter MacCallum Cancer Centre).  After completing his undergraduate education in London he completed a PhD at the University of Melbourne and obtained his Fellowship (FFSc) from the Royal College of Pathologists of Australasia in 2010. He currently administers three TGA issued cGMP manufacturing licences , on behalf of Orthogen Australia Ltd and Mesoblast Ltd (as well as Peter Mac). These services have been subjected to 13 medicines agency inspections over the last 10 years as part of their routine compliance activities. He is currently involved in commercial process development and manufacturing for numerous international clients of Cell Therapy as well as supporting novel research in in-vivo therapy imaging using PET and MRI, complex cell therapy trials (such as GMO T cell immunotherapy for acute leukemia) as well as a maintaining a core routine service for patients with cancer.  He is the Regional (Australasia) Vice-President Elect for the International Society for Cell Therapy.


By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product.



To view this FREE Webinar register here.
Already a member of Pharma IQ? Sign in to register.

First Name:  *
Last Name:  *
Job Title:  *
E-mail:  *
Phone:  *
Company:  *
Country:
User Name:  *
Password:  *
Confirm Password:  *
Which of the following best describes your area of expertise?

1
 Comments
Sign in or Sign up to post a comment
View Profile
  Report Abuse  
DUTTAIN 10/27/2011 2:23:22 PM EDT

EXCELLENT INFORMATION
Replies (0)

Post a Comment
Sign in or Sign up to post a comment
Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Recent Activity

* = required.

Not a member yet? Sign up
User Name:
Password: